RxDoctor Payments Data

Praveen Mehrotra, MD

Cardiovascular Disease · Philadelphia, PANPI 1700058195

Payments from drug & device makers

$63,425in general payments, 2019–2025

Across 112 payments — averaging $566.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$49K
  • GE HealthCare$10K
  • Abbott$2K
  • Edwards Lifesciences$1K
  • Medtronic$628
  • Ancora Heart, Inc.$183
  • plus $515 from 10 others

What the payments were for

  • Speaking & faculty fees$13,74070%
  • Travel & lodging$1,89010%
  • Food & beverage$4,08421%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,425 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$77,169
Medicare patients
615
Services billed
1,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$66,595
EntrestoSacubitril/Valsartan14$24,102
Repatha SureclickEvolocumab27$23,050
MultaqDronedarone Hcl18$22,459
XareltoRivaroxaban12$18,120
Praluent PenAlirocumab14$10,740
Atorvastatin Calcium188$3,518
Metoprolol Succinate104$2,216
Ezetimibe25$1,037
Carvedilol94$985
Eplerenone14$881
Valsartan17$856
Lisinopril53$614
Amlodipine Besylate63$584
Rosuvastatin Calcium43$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$66,59552 claims
NovartisEntresto$112$24,10214 claims
Johnson & JohnsonXarelto$68$18,12012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →